Study Finds Chocolate Good for Everything: True or False?

FDA Expands Evolocumab Indication to Adults at Risk for Major Cardiovascular Events Due to Uncontrolled LDL-C

Slideshow

Can dark chocolate intake decrease depressive symptoms? Is chocolate intake linked to a higher risk of atrial fibrillation? New research examines the impact that chocolate has on various health conditions.

Related Content

2025 AAD Atopic Dermatitis Update: Linda Stein Gold, MD, on New Topical and Biologic Therapies

The FDA removed the prior requirement for a person who is already diagnosed with a cardiovascular disease.

Linda Stein Gold, MD;Sydney Jennings

Lilly’s Oral GLP-1 Orforglipron Meets Endpoints in Phase 3 Obesity and Diabetes Trial

Linda Stein Gold, MD, reviews AAD’s 2025 updates on new topical and biologic options for adult atopic dermatitis.

Countering Vaccine Misinformation in Clinical Practice with Amesh Adalja, MD: Primary Viewpoints Podcast

Orforglipron achieved significant weight loss, A1C reduction, and cardiometabolic benefits in the phase 3 ATTAIN-2 study, supporting upcoming global regulatory submissions.

Amesh Adalja, MD;Sydney Jennings

August 22nd 2025

Semaglutide 2.4 mg Approved for Treatment of MASH Without Cirrhosis: Daily Dose

Infectious disease expert shares strategies for PCPs to counter vaccine myths, navigate policy changes, and build patient trust.

Signos Wins Clearance for First Over-The-Counter CGM for Weight Management

Your daily dose of the clinical news you may have missed.

FDA Clears First Over-The-Counter CGM for Weight Management From Signos / image credit ©lukszczepanski/stock.adobe.com

Grace Halsey

FDA Expands Evolocumab Indication to Adults at Risk for Major Cardiovascular Events Due to Uncontrolled LDL-C

The combination of the Dexcom Stelo glucose biosensor with an AI platform provides real-time data on how food, exercise, stress, and sleep affect the body.

Related Content

2025 AAD Atopic Dermatitis Update: Linda Stein Gold, MD, on New Topical and Biologic Therapies

The FDA removed the prior requirement for a person who is already diagnosed with a cardiovascular disease.

Linda Stein Gold, MD;Sydney Jennings

Lilly’s Oral GLP-1 Orforglipron Meets Endpoints in Phase 3 Obesity and Diabetes Trial

Linda Stein Gold, MD, reviews AAD’s 2025 updates on new topical and biologic options for adult atopic dermatitis.

Countering Vaccine Misinformation in Clinical Practice with Amesh Adalja, MD: Primary Viewpoints Podcast

Orforglipron achieved significant weight loss, A1C reduction, and cardiometabolic benefits in the phase 3 ATTAIN-2 study, supporting upcoming global regulatory submissions.

Amesh Adalja, MD;Sydney Jennings

August 22nd 2025

Semaglutide 2.4 mg Approved for Treatment of MASH Without Cirrhosis: Daily Dose

Infectious disease expert shares strategies for PCPs to counter vaccine myths, navigate policy changes, and build patient trust.

Signos Wins Clearance for First Over-The-Counter CGM for Weight Management

Your daily dose of the clinical news you may have missed.

Grace Halsey